Therapeutics

Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/f5EO50XB6ZL

55% of sites report activation timelines of five months or longer. Our new whitepaper explores why, and how to fix it. Download now: https://ow.ly/j6RK50XB6ZW

Learn how to build a JCA dossier that supports both EU-wide assessments and national reimbursement needs. Download the whitepaper: https://ow.ly/2wWF50XgHL8 #ValueCommunication #HEOR #HTA #ICONInsights

Integrating advanced delivery systems, often accelerated by AI modelling, is a game-changer for biopharmaceutical success. In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, MSc, M...

Want to know what’s missing in next-gen drug delivery? In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, outlines current product development trends happening in the world of bio...

How to navigate EU MAA Regulations and Registration. For Chinese pharma and biotech companies looking to expand into the European Union’s market of over 450 million people, the first step is to understand the significant...

In today’s data-rich healthcare landscape, open claims datasets offer unmatched breadth and timeliness. But disruptions—whether from new sources or supplier exits—are inevitable. Join Symphony Health, an ICON plc compan...

Open claims datasets are a goldmine for life sciences—but they come with inevitable disruptions. Whether it’s new data sources or supplier exits, knowing how to manage change is key to maintaining strategic advantage. J...

The biotech landscape is evolving fast. ICON Biotech’s latest sector surveys reveal what’s changed since 2023, which therapeutic areas are slowing down, and which modalities are gaining momentum. Discover how global geo...

From prescriptions to patient demographics, Metys®, from Symphony Health, an ICON plc company, sees it all. With over 150+ metrics – from diagnosis subgroups to payer mis – you get the full picture, not just a snapshot....

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav...